ECO 2025 - Three-year findings of tirzepatide treatment, a GIP/GLP-1 agonist, for patients with prediabetes observed stable weight loss results and suggests that tirzepatide is a viable option for patients with indication. The study also observed the total weight loss patients may obtain can be predicted within the first month of treatment with tirzepatide.

Prof Luca Busetto (Padova University Hospital, Padova, IT) joins us to discuss the three-year findings from the SURMOUNT-1 study (NCT04184622; Eli Lilly and Company) investigating the efficacy of the phase three development of tirzepatide on body weight in more than 2,500 patients with obesity and overweight. After one-year, a randomised, controlled extension of the study was carried out for three years with a cohort of patients with pre-diabetes. The extension study compared 5mg, 10mg and 15mg dosages of tirzepatide with lifestyle modification against placebo with lifestyle modification.

Interview Questions:
1. What is the background behind the SURMOUNT-1 study?
2. What was the study design and patient population?
3. What were the key findings and how can they be used to identify patients who would benefit most from tirzepatide?
4. What are the take-home messages for practice?
5. What further research is needed in this area and are there specific patient populations who might benefit from this?

Recorded remotely from Padova, 2025.

Editors: Jordan Rance, Yazmin Sadik
Videographers: Oliver Miles

Support: This is an independent interview produced by Radcliffe CVRM.